Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

Inclusion Criteria: * Patients with epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, stages I-IV. These patients must have received initial surgery and chemotherapy with at least one platinum based chemotherapy regimen. * Patients must have relapsed and now have completed chemotherapy for recurrent disease within the last 6 weeks. * Eligible patients may have asymptomatic residual measurable disease on CT scan, and/or may have an elevated CA-125, or may be in complete clinical remission. * Patients must have adequate hematologic, renal and hepatic functions. Exclusion Criteria: * Patients with any other active malignancy concomitantly * Patients within 3 weeks of prior cytotoxic or investigational chemotherapy * Patients within 4 weeks of prior radiotherapy * Patients within 6 weeks of prior immunotherapy * Patients who have received any prior anti-cancer vaccine